文献速递中毒与环境急症重症综合管理与镇静镇痛

伦敦急诊科179例急性消遣性药物中毒中合成大麻素的分析确认

Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015.
PubMed 文献 · Clin Toxicol (Phila) · 2017-02-20
一句话结论在179例急性消遣性药物中毒的急诊患者中,10%的血样检出合成大麻素受体激动剂,但仅半数自报使用。

该观察性队列研究连续纳入2015年1月至7月(6个月)伦敦某急诊科179例急性消遣性药物中毒成人患者,用高分辨率精确质量液相色谱-质谱联用分析常规血清残样。18例(10%)检出合成大麻素受体激动剂,最常见为5F AKB-48(13例,浓度50-7600 pg/ml)。检出者中仅9/18(50%)自报使用。最常见临床表现为癫痫发作和激越,各4例(22%);14例(78%)从急诊出院,入院4例中1例收入重症监护。提示急诊合成大麻素中毒可能比报告更常见。

要点

  • 179例急性消遣性药物中毒成人中18例(10%)血样检出合成大麻素受体激动剂,仅9/18(50%)自报使用。
  • 最常见检出物为5F AKB-48(13例,浓度50-7600 pg/ml),其次5F PB-22(7例,30-400 pg/mL)、MDMB-CHMICA(7例,80-8000 pg/mL)。
  • 最常见临床表现为癫痫发作和激越,各4例(22%)。
  • 14例(78%)从急诊出院,入院4例中1例收入重症监护。

适用人群与场景

  • 2015年1月至7月(6个月)连续就诊于伦敦某急诊科的急性消遣性药物中毒成人患者,共179例。

红旗征与不能漏的情况

  • 癫痫发作和激越为最常见临床表现,各4例(22%)。

研究设计与关键结果

  • 观察性队列研究,纳入179例急性消遣性药物中毒成人患者,采用高分辨率精确质量液相色谱-质谱联用分析常规血清残样。
  • 18例(10%)检出合成大麻素受体激动剂;最常见为5F AKB-48(13例,浓度50-7600 pg/ml),其次5F PB-22(7例,30-400 pg/mL)、MDMB-CHMICA(7例,80-8000 pg/mL)、AB-CHMINACA(3例,50-1800 pg/mL)、Cumyl 5F-PINACA(1例,800 pg/mL)、BB-22(1例,60 pg/mL)。
  • 检出者中仅9/18(50%)自报合成大麻素受体激动剂使用。
  • 最常见临床特征为癫痫发作和激越,各4例(22%);14例(78%)从急诊出院,入院4例中1例收入重症监护。

证据类型、等级与局限

  • 证据类型:观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,急诊急性合成大麻素受体激动剂中毒可能比报告的更常见,因检出者中仅半数自报使用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

CONTEXT: Synthetic cannabinoid receptor agonists are the largest group of new psychoactive substances reported in the last decade; in this study we investigated how commonly these drugs are found in patients presenting to the Emergency Department with acute recreational drug toxicity.

METHODS: We conducted an observational cohort study enrolling consecutive adult patients presenting to an Emergency Department (ED) in London (UK) January-July 2015 (6 months) with acute recreational drug toxicity. Residual serum obtained from a serum sample taken as part of routine clinical care was analyzed using high-resolution accurate mass-spectrometry with liquid-chromatography (HRAM-LCMSMS). Minimum clinical data were obtained from ED medical records.

RESULTS: 18 (10%) of the 179 patient samples were positive for synthetic cannabinoid receptor agonists. The most common was 5F AKB-48 (13 samples, concentration 50-7600 pg/ml), followed by 5F PB-22 (7, 30-400 pg/mL), MDMB-CHMICA (7, 80-8000 pg/mL), AB-CHMINACA (3, 50-1800 pg/mL), Cumyl 5F-PINACA (1, 800 pg/mL) and BB-22 (1, 60 pg/mL). Only 9/18 (50%) in whom synthetic cannabinoid receptor agonists were detected self-reported synthetic cannabinoid receptor agonist use. The most common clinical features were seizures and agitation, both recorded in four (22%) individuals. Fourteen patients (78%) were discharged from the ED, one of the four admitted to hospital was admitted to critical care.

CONCLUSIONS: Synthetic cannabinoid receptor agonists were found in 10% of this cohort with acute recreational drug toxicity but self-reported in only half of these. This suggests that presentations to the ED with acute synthetic cannabinoid receptor agonist toxicity may be more common than reported.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Abouchedid R, Hudson S, Thurtle N, et al. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015. Clin Toxicol (Phila). 2017. PMID: 28421836. doi:10.1080/15563650.2017.1287373

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。